These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35263661)

  • 1. Nasal Glucagon Is Easier to Use and More Preferred and Needs Less Effort to Administer Than Injectable Glucagon: User Perceptions of Glucagon Administration During Severe Hypoglycemia Simulation.
    Settles J; Hinnen D; Spaepen E; Bajpai S; Turakhiya A; Ghodke S; Child CJ
    Endocr Pract; 2022 May; 28(5):486-493. PubMed ID: 35263661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE.
    Settles JA; Gerety GF; Spaepen E; Suico JG; Child CJ
    Endocr Pract; 2020 Apr; 26(4):407-415. PubMed ID: 32293921
    [No Abstract]   [Full Text] [Related]  

  • 3. People With Diabetes and Caregivers Prefer Rescue Glucagon Treatment With a Wider Storage Temperature Range and a Nasal Administration, When Efficacy is Similar: A Discrete Choice Experiment in Spain.
    Mitchell BD; Rentz AM; Kummer S; Yan Y; Heidenreich S; Krucien N; Artime E; Osumili B; Rubio M; Gelhorn HL
    J Diabetes Sci Technol; 2023 Nov; 17(6):1623-1633. PubMed ID: 35533142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.
    Yale JF; Dulude H; Egeth M; Piché CA; Lafontaine M; Carballo D; Margolies R; Dissinger E; Shames AR; Kaplowitz N; Zhang MX; Zhang S; Guzman CB
    Diabetes Technol Ther; 2017 Jul; 19(7):423-432. PubMed ID: 28556672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usability of Nasal Glucagon Device: Partially Randomized Caregiver and Third-Party User Experience Trial with Simulated Administration at a Japanese Site.
    Aranishi T; Nagai Y; Takita Y; Zhang S; Nishimura R
    Diabetes Ther; 2020 Jan; 11(1):197-211. PubMed ID: 31686354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances.
    Bajpai SK; Cambron-Mellott MJ; Peck E; Poon JL; Wang Q; Mitchell BD; Babrowicz J; Child CJ; Raibulet NK; Beusterien K
    Clin Ther; 2019 Oct; 41(10):2073-2089.e6. PubMed ID: 31526655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Usability of Intranasal Glucagon for the Management of Hypoglycemia in Patients With Diabetes: A Systematic Review.
    Singh-Franco D; Moreau C; Levin AD; Rosa D; Johnson M
    Clin Ther; 2020 Sep; 42(9):e177-e208. PubMed ID: 32873417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
    Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
    J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.
    Deeb LC; Dulude H; Guzman CB; Zhang S; Reiner BJ; Piché CA; Pradhan S; Zhang XM
    Pediatr Diabetes; 2018 Aug; 19(5):1007-1013. PubMed ID: 29512902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia.
    Bailey NC; Dimsits J; Hammer M; Kendall DM; Bailey TS
    Diabetes Technol Ther; 2022 Apr; 24(4):231-240. PubMed ID: 34809479
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of Intranasal and Injectable Glucagon Administration Among Pediatric Population Responders.
    Wang YP; Bernatchez F; Chouinard-Castonguay S; Tremblay MC; Vanasse A; Kinnard N; Mégalli M; Millette M; Boulet G; Henderson M; Simoneau-Roy J; Brazeau AS; Rabasa-Lhoret R; Gagnon C
    Diabetes Technol Ther; 2023 Nov; 25(11):808-816. PubMed ID: 37751153
    [No Abstract]   [Full Text] [Related]  

  • 12. Not only for caregivers: intranasal glucagon for severe hypoglycaemia in a simulation study.
    Monzani A; Savastio S; Manzo A; Scalogna A; Pozzi E; Sainaghi PP; Della Corte F; Rabbone I
    Acta Diabetol; 2022 Nov; 59(11):1479-1484. PubMed ID: 35951133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
    Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
    J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
    [No Abstract]   [Full Text] [Related]  

  • 14. Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation.
    Valentine V; Newswanger B; Prestrelski S; Andre AD; Garibaldi M
    Diabetes Technol Ther; 2019 Sep; 21(9):522-530. PubMed ID: 31219349
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.
    Seaquist ER; Dulude H; Zhang XM; Rabasa-Lhoret R; Tsoukas GM; Conway JR; Weisnagel SJ; Gerety G; Woo VC; Zhang S; Carballo D; Pradhan S; Piché CA; Guzman CB
    Diabetes Obes Metab; 2018 May; 20(5):1316-1320. PubMed ID: 29504662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Needle-free nasal delivery of glucagon for treatment of diabetes-related severe hypoglycemia: toxicology of polypropylene resin used in delivery device.
    Reno FE; Edwards CN; Bendix Jensen M; Török-Bathó M; Esdaile DJ; Piché C; Triest M; Carballo D
    Cutan Ocul Toxicol; 2016 Sep; 35(3):242-7. PubMed ID: 26426957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal Glucagon: A New Way to Treat Hypoglycemic Emergencies.
    Lowe RN; Trujillo JM
    Ann Pharmacother; 2020 Aug; 54(8):780-787. PubMed ID: 32052651
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis.
    Yale JF; Osumili B; Mitchell BD; Hunt B; Sohi G; Jeddi M; Mojdami D; Valentine WJ
    J Med Econ; 2022; 25(1):238-248. PubMed ID: 35094622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human factors studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation.
    Newswanger B; Prestrelski S; Andre AD
    Expert Opin Drug Deliv; 2019 Sep; 16(9):1015-1025. PubMed ID: 31475853
    [No Abstract]   [Full Text] [Related]  

  • 20. Intranasal Glucagon.
    Kalra S; Dhingra M
    J Pak Med Assoc; 2019 Aug; 69(8):1219-1221. PubMed ID: 31431785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.